Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous TILs in Advanced Solid Tumors
NCT04967833Phase 1Recruiting
- Sponsor
- Juncell Therapeutics
- Start
- Apr 2021
- Primary completion
- Dec 2027
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous tumor-infiltrating lymphocytes in solid tumor, sponsored by Juncell Therapeutics. Primary endpoints: Adverse Events at 6 months and Objective Response Rate up to 36 months. Started Apr 2021; status: recruiting.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04967833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04967833.